INS and Hypoglycemia: With current basal insulins, this attribute was manifested in the second-generationonce-daily basal insulin analogues, IDeg and IGlar U300, which demonstrated longertime-action profiles and lower hypoglycemia risk compared to IGlar U100 (10-16).